AMACR/p504s Recombinant Rabbit mAb (SDT-401-29)

產(chǎn)品型號(hào)：S0B2189

更新時(shí)間：2025-08-08

廠商性質(zhì)：生產(chǎn)廠家

訪(fǎng)問(wèn)量：143

服務(wù)熱線(xiàn)

15855403091

立即咨詢(xún)

產(chǎn)品分類(lèi)

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對(duì)抗體病理/IHC抗體

查看全部產(chǎn)品

CDx 抗體 | 新興靶點(diǎn)B7-H3/H4，助力ADC藥物研發(fā)

如何選擇合適的偶聯(lián)抗體用于實(shí)驗(yàn)研究？

免疫組化新助力：幽門(mén)螺旋桿菌(Hp)重組兔單抗上線(xiàn)！

產(chǎn)品介紹

α-Methylacyl-CoA racemase （AMACR; P504S） catalyzes a key chiral inversion step in the metabolism of branched-chain fatty acids, ibuprofen and related drugs. Protein levels are increased in all prostate and some other cancer cells and it is used as a marker （P504S）. The enzyme requires no cofactors and catalyzes its reaction by a stepwise 1,1-proton transfer via an enolate intermediate. The biological role of AMACR in cancer is complex, linking lipid metabolism with nuclear receptor （e.g. FXR and PPAR） activity and expression of enzymes such as cyclooxygenase-2 （COX-2）. A number of rationally designed AMACR inhibitors have been reported in the literature as potential cancer treatments. The opportunities and challenges for development of acyl-CoA esters as inhibitors are discussed from a medicinal chemical viewpoint. Other challenges for drug development include the problems in assaying enzymatic activity and the prediction of structure-activity relationships （SAR）. [PMID: 23376124]

上一個(gè)：S0B0101Invivo anti-mouse PD-1 Recombinant mAb (RMP1-14)